Astellas Pharma and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin
Astellas Pharma and Seattle Genetics announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or…
Read More...
Read More...
